Table 3.

Interactions of asthma, allergy with COVID-19 in children

Topic	Main findings	References
Prevalence of allergy and asthma in 107 COVID-19 children	The prevalence of AR, asthma, AD and episodic wheezing were 10.3%, 6.5%, 4.7% and 3.7% respectively in pediatric COVID-19 patients. Asthma and allergy are not risk factors for hospitalization of COVID-19.	(58)
182 pediatric COVID-19 cases	Allergy did not impact disease incidence, clinical features, laboratory and immunological findings of COVID-19, and was not a risk factor for infection and severity of COVID-19 in children	(59)
Prevalence of allergy and asthma in 40 COVID-19 children	Prevalence of allergy was 5.0% in COVID-19 children, lower than that in pediatric population (32.2%). Prevalence of asthma was 2.5% and lower than that in pediatric population (11.6%)	(60)
Asthma children with COVID-19	Children with asthma had more symptoms of COVID-19 and higher rate of hospitalization, but no difference in the severity and laboratory findings compared with children without asthma	(61)
Childhood asthma outcomes during COVID-19	Childhood with asthma had a better asthma control and improved lung function during COVID-19, may be due to reduced exposure to triggers	(62)
Children with AR and asthma during COVID-19	A general trend of clinical improvement and a reduction in the use of on-demand and basal therapy in allergic children during the lockdown	(63)